BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30702464)

  • 21. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
    Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas.
    Wappenschmidt B; Wardelmann E; Gehrig A; Schöndorf T; Maass N; Bonatz G; Gassel AM; Pietsch T; Mallmann P; Weber BH; Schmutzler RK
    Hum Pathol; 2004 Oct; 35(10):1260-5. PubMed ID: 15492994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
    Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
    Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer.
    Travaglino A; Raffone A; Saccone G; De Luca C; Mollo A; Mascolo M; De Placido G; Insabato L; Zullo F
    Am J Clin Pathol; 2019 Apr; 151(5):529-538. PubMed ID: 30715091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
    Travaglino A; Raffone A; Raimondo D; Reppuccia S; Ruggiero A; Arena A; Casadio P; Zullo F; Insabato L; Seracchioli R; Mollo A
    Arch Gynecol Obstet; 2022 Aug; 306(2):423-431. PubMed ID: 35034160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
    Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
    Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
    Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
    Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant treatment in early-stage endometrial cancer: context-dependent impact of somatic
    Kurnit KC; Fellman BM; Mills GB; Bowser JL; Xie S; Broaddus RR
    Int J Gynecol Cancer; 2022 Jul; 32(7):869-874. PubMed ID: 35483739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations.
    Jiang Y; Malouf GG; Zhang J; Zheng X; Chen Y; Thompson EJ; Weinstein JN; Yuan Y; Spano JP; Broaddus R; Tannir NM; Khayat D; Lu KH; Su X
    Oncotarget; 2015 Nov; 6(37):39865-76. PubMed ID: 26431491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium.
    Geels YP; van der Putten LJ; van Tilborg AA; Lurkin I; Zwarthoff EC; Pijnenborg JM; van den Berg-van Erp SH; Snijders MP; Bulten J; Visscher DW; Dowdy SC; Massuger LF
    Gynecol Oncol; 2015 May; 137(2):245-51. PubMed ID: 25773202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CTNNB1 p.D32A (c.95A > C) somatic mutation in stage I grade 1 endometrioid endometrial carcinoma with lung metastasis: a case report.
    Zhong L; Jiang W; RutieYin ; Liu H; Song L
    BMC Med Genomics; 2023 Jun; 16(1):137. PubMed ID: 37328769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
    Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
    J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Jones NL; Xiu J; Rocconi RP; Herzog TJ; Winer IS
    Gynecol Oncol; 2020 Feb; 156(2):393-399. PubMed ID: 31882243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
    Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations.
    Irving JA; Lee CH; Yip S; Oliva E; McCluggage WG; Young RH
    Am J Surg Pathol; 2015 Oct; 39(10):1420-6. PubMed ID: 26200099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and pathologic data to guide selection of patients with endometrioid endometrial cancer for ovarian preservation.
    Manning-Geist BL; Rios-Doria E; Liu YL; Ellenson LH; Zhou QC; Iasonos A; Leitao MM; Abu-Rustum NR; Weigelt B; Mueller JJ
    Int J Gynecol Cancer; 2024 May; 34(5):697-704. PubMed ID: 38508587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Stasenko M; Tunnage I; Ashley CW; Rubinstein MM; Latham AJ; Da Cruz Paula A; Mueller JJ; Leitao MM; Friedman CF; Makker V; Soslow RA; DeLair DF; Hyman DM; Zamarin D; Alektiar KM; Aghajanian CA; Abu-Rustum NR; Weigelt B; Cadoo KA
    Gynecol Oncol; 2020 Jan; 156(1):194-202. PubMed ID: 31757464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas.
    Machin P; Catasus L; Pons C; Muñoz J; Matias-Guiu X; Prat J
    Hum Pathol; 2002 Feb; 33(2):206-12. PubMed ID: 11957146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.